CO5050328A1 - SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS - Google Patents

SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS

Info

Publication number
CO5050328A1
CO5050328A1 CO98017937A CO98017937A CO5050328A1 CO 5050328 A1 CO5050328 A1 CO 5050328A1 CO 98017937 A CO98017937 A CO 98017937A CO 98017937 A CO98017937 A CO 98017937A CO 5050328 A1 CO5050328 A1 CO 5050328A1
Authority
CO
Colombia
Prior art keywords
solvent system
pharmaceutical compounds
best penetration
penetration
composition
Prior art date
Application number
CO98017937A
Other languages
Spanish (es)
Inventor
S Rao Chakradhara
Liu Jue-Chen
Jonas C T Wang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of CO5050328A1 publication Critical patent/CO5050328A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

SE DESCRIBE UNA COMPOSICION QUE CONSISTE DE UN COM PUESTO O DROGA FARMACEUTICAMENTE TOPICAMENTE ACTI- VO Y UN SISTEMA SOLVENTE BUFFER CAPAZ DE MEJORAR LA PENETRACION DE DICHA DROGA. EL SISTEMA SOLVEN- TE BUFFER PERMITE A UNA CANTIDAD REDUCIDA DEL COM- PUESTO FARMACEUTICO DE LA COMPOSICION NO ALTERAR SIGNIFICATIVAMENTE LA EFICACIA DE DICHO COMPUESTO.A COMPOSITION IS DESCRIBED WHICH CONSISTS OF A PHARMACEUTICALLY TOPICALLY ACTIVENT COMMITTEE OR DRUG AND A SOLELY BUFFER SYSTEM ABLE TO IMPROVE THE PENETRATION OF THE DRUG. THE BUFFER SOLVING SYSTEM ALLOWS A REDUCED AMOUNT OF THE PHARMACEUTICAL COMPOSITION COMPOSITION NOT TO SIGNIFICANTLY ALTER THE EFFECTIVENESS OF THIS COMPOSITE.

CO98017937A 1997-03-31 1998-03-31 SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS CO5050328A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
CO5050328A1 true CO5050328A1 (en) 2001-06-27

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98017937A CO5050328A1 (en) 1997-03-31 1998-03-31 SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS

Country Status (14)

Country Link
EP (1) EP0971746A1 (en)
JP (1) JP2001518879A (en)
KR (1) KR19980081207A (en)
CN (1) CN1252003A (en)
AR (1) AR012217A1 (en)
AU (1) AU6677698A (en)
BR (1) BR9811458A (en)
CA (1) CA2285368A1 (en)
CO (1) CO5050328A1 (en)
HU (1) HUP0001739A3 (en)
IL (1) IL132096A0 (en)
PL (1) PL335934A1 (en)
WO (1) WO1998043673A1 (en)
ZA (1) ZA982662B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
AU5146600A (en) * 1999-05-27 2000-12-18 Procter & Gamble Company, The Topical compositions providing improved treatment of skin or scalp fungal infections
GB0103046D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP4784051B2 (en) * 2003-07-03 2011-09-28 大正製薬株式会社 Antifungal composition for external use that prevents adsorption to the container
JP5435836B2 (en) * 2003-07-03 2014-03-05 大正製薬株式会社 Antifungal composition for external use
DE102005059742A1 (en) 2005-12-13 2007-06-14 Beiersdorf Ag Transparent sunscreen
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
SI2079441T1 (en) * 2007-07-25 2010-12-31 Ixodes Gmbh Topical antibiotic composition for the prevention of lyme disease
US8492421B2 (en) 2007-08-27 2013-07-23 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
MX363386B (en) 2013-10-03 2019-03-20 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions.
KR102612453B1 (en) 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 Anti-infective methods, compositions, and devices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition

Also Published As

Publication number Publication date
HUP0001739A3 (en) 2001-04-28
IL132096A0 (en) 2001-03-19
CN1252003A (en) 2000-05-03
KR19980081207A (en) 1998-11-25
AR012217A1 (en) 2000-09-27
ZA982662B (en) 1999-09-30
BR9811458A (en) 2000-09-19
WO1998043673A1 (en) 1998-10-08
HUP0001739A2 (en) 2000-12-28
EP0971746A1 (en) 2000-01-19
CA2285368A1 (en) 1998-10-08
JP2001518879A (en) 2001-10-16
AU6677698A (en) 1998-10-22
PL335934A1 (en) 2000-05-22

Similar Documents

Publication Publication Date Title
CO5050328A1 (en) SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS
GT199900070A (en) DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
ECSP003682A (en) COMPOUNDS FOR THE TREATMENT OF THE ISCHEMIA
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
GT199700089A (en) DERIVATIVES 6.6 OR 6.7-SUBSTITUTED BICYCLES CONTAINING PIRIDO OR PIRIMIDO.
AR058193A1 (en) PHARMACEUTICAL COMPOSITIONS
UY27943A1 (en) COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS
GT199700079A (en) TRICYCLES DERIVATIVES REPLACED WITH PHENYLAMINE
BR0015605A (en) Composition and use
MX9505182A (en) Therapeutical composition for topical application, containing a p substance antagonist.
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
AR025052A1 (en) DERIVATIVES OF 2-DIALQUILAMINOALQUILBIFENILO SUBSTITUTED, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THE USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES.
KR960701661A (en) HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS
AR021912A1 (en) USE OF APOMORPHINE FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN VARONES
AR042051A1 (en) COMBINED TREATMENT AGAINST CANCER WITH AN ANTI-CANCERIGENE COMPOUND ACTIVATED BY GLUTATIONA S- TRANSFERASA (GST) AND OTHER TREATMENT AGAINST CANCER
MX9306220A (en) PTP 1D: A NOVYOSE THYROSINE PHOSPHATASE PROTEIN.
AR054806A1 (en) FORMULATIONS OF CONJUGATED STROGENS AND BAZEDOXIFEN
AR003119A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING VIROSIC INFECTIONS OR INHIBITING THE GROWTH OF TUMORS OR CANCERES WHICH INCLUDE A MIXTURE OF A N-CHLOROPHENYL CARBAMATE OR A N-CHLOROPHENITIC CARBAMATE AND A N- PHOSPHONOGLYCAN FOR DICHAUTIC DURATION INHIBIT THE GROWTH OF TUMORS OR CANCERS
AR003176A1 (en) A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER
AR006401A1 (en) PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.
BR0208017A (en) Combination comprising combretastatin and anticancer agents
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
BR9916575A (en) Pharmaceutical composition of controlled release with tilidine mesylate as active substance
CO5570661A2 (en) COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS